logo

Aurinia Pharmaceuticals Inc. (AUPH)



Trade AUPH now with
  Date
  Headline
8/17/2021 6:09:10 AM Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune And Kidney-related Diseases
6/7/2021 7:24:47 AM Aurinia Announces Additional Analysis Of AURORA 1 Phase 3 Study Data Presented At ERA-EDTA 2021 Congress
4/8/2021 6:08:36 AM Aurinia Pharma Presents Addl Efficacy Data From AURA-LV And AURORA 1 Pivotal Trials Of LUPKYNIS In Lupus Nephritis
3/15/2021 6:15:45 AM Aurinia Announces Positive Cost-Effectiveness Assessment Of LUPKYNIS In Latest ICER Draft Evidence Report
2/22/2021 1:32:00 AM New Drugs Approved In January
12/17/2020 4:03:54 AM Aurinia Announces Collaboration Deal With Otsuka Pharma For Development Of Voclosporin In Europe And Japan
9/28/2020 6:09:40 AM Aurinia Completes Final Patient Treatment In AUDREY Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution
7/27/2020 10:34:12 AM Aurinia Closes $200 Mln Public Offering Of Common Shares
7/22/2020 11:11:24 PM Aurinia Pharma Announces Pricing Of Underwritten Public offering Of 13.33 Mln Shares At US$15.00/shr
6/22/2020 6:09:21 AM Aurinia Completes Patient Enrollment Into AUDREY Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution